Kidney Disease and Pulmonary Hypertension

Study Overview
=================
Brief Summary
-----------------
Evaluation of the prevalence of kidney disease, hemodynamic predictors and long-term renal outcome in patients with invasively diagnosed pulmonary hypertension.

Detailed Description
-----------------
This study aims to determine the prevalence of kidney disease, hemodynamic predictors and long-term renal outcome of in-hospital patients with invasively diagnosed pulmonary hypertension at the Department of Pulmonology, University Hospital Giessen and Marburg, Giessen, Germany between 1999 and 2016.

Official Title
-----------------
Prevalence and Predictors of Kidney Disease, and Long-Term Renal Outcome in Pulmonary Hypertension

Conditions
-----------------
Pulmonary Hypertension

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: older than 18 years subjects with invasively diagnosed pulmonary hypertension at rest and available renal function and spot urine data at day of right heart catheterization between March 1999 and December 2016 at the Department of Pulmonology, University Hospital Giessen and Marburg, Giessen, Germany Exclusion Criteria: subjects with estimated GFR <15ml/min/1.73m2 or prior dialysis pre-existing acute kidney injury non-end stage renal disease with extracorporeal or peritoneal ultrafiltration due to diuretic-resistant fluid overload primary kidney disease requiring active immunosuppression autosomal dominant polycystic kidney disease if subjects are pregnant if subjects are recipients of solid-organ transplants subjects with pulmonary hypertension with unclear/multifactorial mechanisms (WHO group 5 pulmonary hypertension)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|No intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in estimated glomerular filtration rate (GFR) in each class of pulmonary hypertension during follow-up period | Estimated GFR (Chronic Kidney Disease Epidemiology Collaboration) will be used over follow-up period to determine changes in renal function | 3 years follow-up | 
| Impact of renal function on deterioration of pulmonary hypertension during follow-up period | Changes in estimated GFR (Chronic Kidney Disease Epidemiology Collaboration) over follow-up period will be correlated with clinical worsening of pulmonary hypertension (as determined by echocardiography, 6-minute-walk, New York Heart Association classification, b-type natriuretic peptide) | 3 years follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of pulmonary hypertension-related morbidity on renal function decline | Severity of pulmonary hypertension (progress pulmonary hypertension, unscheduled hospitalization due to worsening of pulmonary hypertension, mortality) will be correlated with changes in renal function (as determined by estimated GFR [Chronic Kidney Disease Epidemiology Collaboration]) | 3 years follow-up | 
| Prevalence of proteinuria in pulmonary hypertension | 24 hours urine collection at baseline will be assessed to predict progress of pulmonary hypertension | At baseline | 
| Impact of pulmonary hypertension-specific therapy on renal function decline | Estimated GFR (Chronic Kidney Disease Epidemiology Collaboration) over follow-up period will be assessed to show association of pulmonary hypertension-specific therapy on renal function | 3 years follow-up |